Capricor publishes investor presentation on deramiocel Duchenne muscular dystrophy program

• Capricor highlighted FDA review of deramiocel for Duchenne muscular dystrophy with a PDUFA target action date of Aug. 22, 2026.
• HOPE-3 Phase 3 trial (n=106) met the primary endpoint on PUL v2.0 (p=0.03); key cardiac endpoint LVEF also reached significance (p=0.04).
• Presentation framed deramiocel as mutation-agnostic, positioning it for broad use in DMD, including alongside gene therapies or exon-skipping drugs.
• Manufacturing readiness emphasized, citing an operational San Diego GMP facility with FDA pre-license inspection completed in 2025.
• Capricor reported $279 million cash, runway through 2027, 57,900,000 shares outstanding, potential PRV sale estimate of about $150-200 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capricor Therapeutics Inc. published the original content used to generate this news brief on May 28, 2026, and is solely responsible for the information contained therein.